Opinion
Video
Use and Sequencing of Novel Treatments in NMIBC
Author(s):
Experts discuss where they are using FDA-approved treatments for bacille Calmette-Guérin (BCG)–unresponsive patients in their practice, how they choose between these treatments, and how these advances have impacted the timing of radical cystectomy for patients.
Video Player is loading.
Video content above is prompted by the following:
- Where are you using these treatments in your practice, and how do you choose between them for BCG-unresponsive patients?
- How have these advances changed the timing of radical cystectomy for patients?
Related Videos
Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
Treatment or Lack of Treatment of Small Renal Masses
The current treatment landscape of mHSPC
Strengths and Weaknesses of Imaging Modalities in ccRCC
BPH: Strategies for Guiding Patients From Medication to Intervention
Representation of Black men with mHSPC in clinical trials
Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
Non–Muscle Invasive-Bladder Cancer Overview
NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up
BRCA Mutations in mHSPC: Impact on Therapy Selection
Related Content
